Literature DB >> 23313068

CD30-positive cutaneous T-cell lymphoma and response to Brentuximab Vedotin: 2 illustrative cases.

Kabir Mody1, Jill S Wallace, Diane M Stearns, George Bowers, Shannon R Lacy, Norman B Levy, Kathryn A Zug, Frederick Lansigan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23313068     DOI： 10.1016/j.clml.2012.12.008

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma Leuk        ISSN： 2152-2669


× No keyword cloud information.
  3 in total

Review 1.  Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review.

Authors:  Garrett K Berger; Ali McBride; Stephanie Lawson; Kelsey Royball; Seongseok Yun; Kevin Gee; Irbaz Bin Riaz; Ahlam A Saleh; Soham Puvvada; Faiz Anwer
Journal:  Crit Rev Oncol Hematol       Date:  2016-11-21       Impact factor: 6.312

2.  CD30-positive cutaneous lymphoma: report of four cases with an emphasis on clinicopathological correlations.

Authors:  Thiago Jeunon de Sousa Vargas; Samira Barroso Jorge; Yung Bruno de Mello Gonzaga
Journal:  An Bras Dermatol       Date:  2017 Jan-Feb       Impact factor: 1.896

3.  Primary cutaneous anaplastic large cell lymphoma arising from a long-standing erythema nodosum: A case report.

Authors:  Liang-Liang Ma; Shi-Xin Han; Mei-Yun Fang
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.817
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.